OBJECTIVE: To investigate risk factors for Creutzfeldt-Jakob disease (CJD) in patients in the United Kingdom treated with human pituitary growth hormone (hGH). METHODS: Incidence rates of CJD, based on person-year denominators, were assessed in a cohort of 1,848 patients treated with hGH in the United Kingdom from 1959 through 1985 and followed to the end of 2000. RESULTS: CJD developed in 38 patients. Risk of CJD was significantly increased by treatment with hGH prepared by the Wilhelmi method of extraction from human pituitaries. Risk was further raised if this treatment was administered at ages 8 to 10 years. The peak risk of CJD was estimated to occur 20 years after first exposure, and the estimated lifetime cumulative risk of CJD in Wilhelmi-treated patients was 4.5%. CONCLUSIONS: Size-exclusion chromatography, used in non-Wilhelmi preparation methods, may prevent CJD infection. Susceptibility to CJD may vary with age, and susceptibility may be present in only a few percent of the population.
OBJECTIVE: To investigate risk factors for Creutzfeldt-Jakob disease (CJD) in patients in the United Kingdom treated with humanpituitary growth hormone (hGH). METHODS: Incidence rates of CJD, based on person-year denominators, were assessed in a cohort of 1,848 patients treated with hGH in the United Kingdom from 1959 through 1985 and followed to the end of 2000. RESULTS:CJD developed in 38 patients. Risk of CJD was significantly increased by treatment with hGH prepared by the Wilhelmi method of extraction from human pituitaries. Risk was further raised if this treatment was administered at ages 8 to 10 years. The peak risk of CJD was estimated to occur 20 years after first exposure, and the estimated lifetime cumulative risk of CJD in Wilhelmi-treated patients was 4.5%. CONCLUSIONS: Size-exclusion chromatography, used in non-Wilhelmi preparation methods, may prevent CJD infection. Susceptibility to CJD may vary with age, and susceptibility may be present in only a few percent of the population.
Authors: Zane Jaunmuktane; Simon Mead; Matthew Ellis; Jonathan D F Wadsworth; Andrew J Nicoll; Joanna Kenny; Francesca Launchbury; Jacqueline Linehan; Angela Richard-Loendt; A Sarah Walker; Peter Rudge; John Collinge; Sebastian Brandner Journal: Nature Date: 2015-09-10 Impact factor: 49.962
Authors: F M Brett; S Looby; A Chalissery; D Chen; C Heaney; J Heffernan; F Cunningham; R Howley; T Loftus; H Kearney; M A Farrell Journal: Ir J Med Sci Date: 2017-08-12 Impact factor: 1.568
Authors: Silvia A Purro; Mark A Farrow; Jacqueline Linehan; Tamsin Nazari; David X Thomas; Zhicheng Chen; David Mengel; Takashi Saito; Takaomi Saido; Peter Rudge; Sebastian Brandner; Dominic M Walsh; John Collinge Journal: Nature Date: 2018-12-13 Impact factor: 49.962
Authors: Jesús de Pedro-Cuesta; Ignacio Mahillo-Fernandez; Miguel Calero; Alberto Rábano; Mabel Cruz; Åke Siden; Pablo Martínez-Martín; Henning Laursen; María Ruiz-Tovar; Kåre Mølbak Journal: PLoS One Date: 2014-10-03 Impact factor: 3.240
Authors: Jesús de Pedro-Cuesta; Pablo Martínez-Martín; Alberto Rábano; Enrique Alcalde-Cabero; Fernando José García López; Javier Almazán-Isla; María Ruiz-Tovar; Maria-José Medrano; Fuencisla Avellanal; Olga Calero; Miguel Calero Journal: J Alzheimers Dis Date: 2016 Impact factor: 4.472
Authors: Peter Rudge; Zane Jaunmuktane; Peter Adlard; Nina Bjurstrom; Diana Caine; Jessica Lowe; Penny Norsworthy; Holger Hummerich; Ron Druyeh; Jonathan D F Wadsworth; Sebastian Brandner; Harpreet Hyare; Simon Mead; John Collinge Journal: Brain Date: 2015-08-11 Impact factor: 13.501